S&P 500   3,971.01 (-0.16%)
DOW   32,496.25 (+0.20%)
QQQ   306.06 (-0.87%)
AAPL   156.83 (-0.92%)
MSFT   273.47 (-1.05%)
META   200.02 (-1.39%)
GOOGL   100.46 (-1.95%)
AMZN   97.54 (-0.51%)
TSLA   189.38 (-1.27%)
NVDA   262.69 (-0.99%)
NIO   9.13 (+2.24%)
BABA   95.81 (+11.25%)
AMD   94.19 (-2.50%)
T   18.92 (+0.26%)
F   11.57 (+0.43%)
MU   58.58 (-2.02%)
CGC   1.86 (-1.06%)
GE   92.86 (-0.48%)
DIS   95.35 (-0.28%)
AMC   4.66 (+2.42%)
PFE   40.10 (-0.30%)
PYPL   72.78 (-0.71%)
NFLX   328.52 (+0.26%)
S&P 500   3,971.01 (-0.16%)
DOW   32,496.25 (+0.20%)
QQQ   306.06 (-0.87%)
AAPL   156.83 (-0.92%)
MSFT   273.47 (-1.05%)
META   200.02 (-1.39%)
GOOGL   100.46 (-1.95%)
AMZN   97.54 (-0.51%)
TSLA   189.38 (-1.27%)
NVDA   262.69 (-0.99%)
NIO   9.13 (+2.24%)
BABA   95.81 (+11.25%)
AMD   94.19 (-2.50%)
T   18.92 (+0.26%)
F   11.57 (+0.43%)
MU   58.58 (-2.02%)
CGC   1.86 (-1.06%)
GE   92.86 (-0.48%)
DIS   95.35 (-0.28%)
AMC   4.66 (+2.42%)
PFE   40.10 (-0.30%)
PYPL   72.78 (-0.71%)
NFLX   328.52 (+0.26%)
S&P 500   3,971.01 (-0.16%)
DOW   32,496.25 (+0.20%)
QQQ   306.06 (-0.87%)
AAPL   156.83 (-0.92%)
MSFT   273.47 (-1.05%)
META   200.02 (-1.39%)
GOOGL   100.46 (-1.95%)
AMZN   97.54 (-0.51%)
TSLA   189.38 (-1.27%)
NVDA   262.69 (-0.99%)
NIO   9.13 (+2.24%)
BABA   95.81 (+11.25%)
AMD   94.19 (-2.50%)
T   18.92 (+0.26%)
F   11.57 (+0.43%)
MU   58.58 (-2.02%)
CGC   1.86 (-1.06%)
GE   92.86 (-0.48%)
DIS   95.35 (-0.28%)
AMC   4.66 (+2.42%)
PFE   40.10 (-0.30%)
PYPL   72.78 (-0.71%)
NFLX   328.52 (+0.26%)
S&P 500   3,971.01 (-0.16%)
DOW   32,496.25 (+0.20%)
QQQ   306.06 (-0.87%)
AAPL   156.83 (-0.92%)
MSFT   273.47 (-1.05%)
META   200.02 (-1.39%)
GOOGL   100.46 (-1.95%)
AMZN   97.54 (-0.51%)
TSLA   189.38 (-1.27%)
NVDA   262.69 (-0.99%)
NIO   9.13 (+2.24%)
BABA   95.81 (+11.25%)
AMD   94.19 (-2.50%)
T   18.92 (+0.26%)
F   11.57 (+0.43%)
MU   58.58 (-2.02%)
CGC   1.86 (-1.06%)
GE   92.86 (-0.48%)
DIS   95.35 (-0.28%)
AMC   4.66 (+2.42%)
PFE   40.10 (-0.30%)
PYPL   72.78 (-0.71%)
NFLX   328.52 (+0.26%)
NASDAQ:ABIO

ARCA biopharma - ABIO Competitors

$2.01
-0.06 (-2.90%)
(As of 03/28/2023 10:57 AM ET)
Add
Compare
Today's Range
$2.00
$2.09
50-Day Range
$2.02
$2.34
52-Week Range
$1.76
$2.70
Volume
11,034 shs
Average Volume
31,841 shs
Market Capitalization
$29.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ABIO vs. BMRA, NYMX, OCX, TRIB, ICCC, NAVB, VRAX, LHDX, AWH, and MYMD

Should you be buying ARCA biopharma stock or one of its competitors? The main competitors of ARCA biopharma include Biomerica (BMRA), Nymox Pharmaceutical (NYMX), OncoCyte (OCX), Trinity Biotech (TRIB), ImmuCell (ICCC), Navidea Biopharmaceuticals (NAVB), Virax Biolabs Group (VRAX), Lucira Health (LHDX), Aspira Women's Health (AWH), and MyMD Pharmaceuticals (MYMD). These companies are all part of the "diagnostic substances" industry.

ARCA biopharma vs.

Biomerica (NASDAQ:BMRA) and ARCA biopharma (NASDAQ:ABIO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, community ranking, risk, profitability, valuation and earnings.

Biomerica has higher revenue and earnings than ARCA biopharma. Biomerica is trading at a lower price-to-earnings ratio than ARCA biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biomerica$18.87 million1.76-$4.53 million-$0.43-4.60
ARCA biopharmaN/AN/A-$9.93 million-$0.69-2.91

In the previous week, ARCA biopharma had 3 more articles in the media than Biomerica. MarketBeat recorded 4 mentions for ARCA biopharma and 1 mentions for Biomerica. Biomerica's average media sentiment score of 1.11 beat ARCA biopharma's score of 0.58 indicating that Biomerica is being referred to more favorably in the media.

Company Overall Sentiment
Biomerica Positive
ARCA biopharma Positive

Biomerica has a beta of -0.53, meaning that its share price is 153% less volatile than the S&P 500. Comparatively, ARCA biopharma has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500.

ARCA biopharma has a net margin of 0.00% compared to Biomerica's net margin of -34.58%. ARCA biopharma's return on equity of -22.39% beat Biomerica's return on equity.

Company Net Margins Return on Equity Return on Assets
Biomerica -34.58% -66.11% -44.58%
ARCA biopharma N/A -22.39% -21.21%

Biomerica received 14 more outperform votes than ARCA biopharma when rated by MarketBeat users. Likewise, 67.82% of users gave Biomerica an outperform vote while only 51.46% of users gave ARCA biopharma an outperform vote.

CompanyUnderperformOutperform
BiomericaOutperform Votes
137
67.82%
Underperform Votes
65
32.18%
ARCA biopharmaOutperform Votes
123
51.46%
Underperform Votes
116
48.54%

22.0% of Biomerica shares are held by institutional investors. Comparatively, 15.4% of ARCA biopharma shares are held by institutional investors. 15.7% of Biomerica shares are held by insiders. Comparatively, 20.3% of ARCA biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biomerica
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
ARCA biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Summary

Biomerica and ARCA biopharma tied by winning 7 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABIO vs. The Competition

MetricARCA biopharmaDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$29.97M$2.07B$4.34B$5.77B
Dividend YieldN/A0.85%2.40%4.51%
P/E Ratio-2.9130.4994.7512.02
Price / SalesN/A101.073,409.8856.74
Price / CashN/A33.1919.6358.02
Price / Book0.708.514.525.04
Net Income-$9.93M$24.17M$114.61M$190.78M
7 Day Performance-4.74%-3.54%-0.46%-0.65%
1 Month Performance-8.64%-8.09%-6.88%-6.20%
1 Year Performance-13.73%-36.22%-14.33%-17.34%

ARCA biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BMRA
Biomerica
0 of 5 stars
$1.86
-16.6%
N/A-53.4%$31.27M$18.87M-4.3366Positive News
High Trading Volume
NYMX
Nymox Pharmaceutical
0 of 5 stars
$0.41
+14.0%
N/A-68.5%$32.15M$-5,000.00-4.073Upcoming Earnings
Positive News
Gap Down
OCX
OncoCyte
2.2549 of 5 stars
$0.25
-10.9%
$1.35
+450.6%
N/A$29.09M$7.73M-0.38N/AUpcoming Earnings
Short Interest ↑
TRIB
Trinity Biotech
1.1343 of 5 stars
$0.94
+2.2%
N/A-18.3%$35.64M$76.27M-0.86543
ICCC
ImmuCell
0 of 5 stars
$5.22
-2.6%
N/A-51.8%$40.44M$18.57M-17.3960Gap Down
NAVB
Navidea Biopharmaceuticals
0 of 5 stars
$0.32
-6.0%
N/A-66.7%$10.13M$530,000.00-0.55N/A
VRAX
Virax Biolabs Group
0 of 5 stars
$0.75
+5.6%
N/AN/A$9.60M$120,000.000.00N/APositive News
LHDX
Lucira Health
1.9908 of 5 stars
$0.21
-8.7%
N/A-94.2%$8.42M$212.13M-0.06114Gap Down
AWH
Aspira Women's Health
1.9548 of 5 stars
$0.50
+4.2%
$2.00
+300.0%
-63.7%$62.30M$6.81M-1.85106Analyst Revision
MYMD
MyMD Pharmaceuticals
0 of 5 stars
$1.68
-11.6%
N/A-60.0%$66.31MN/A-4.676Upcoming Earnings
Short Interest ↑
This page (NASDAQ:ABIO) was last updated on 3/28/2023 by MarketBeat.com Staff